|
|
 |
|
Viewing report
|
|
|
Sanofi - Aventis seals Licensing Deal with Glenmark for $613m
GlobalData, May 2011, Pages: 4
Sanofi - Aventis seals Licensing Deal with Glenmark for $613m - Deal Analysis from GlobalData
Summary
May 16, 2011 witnessed the commencement of the licensing deal between Glenmark Pharmaceuticals S.A (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India, and Sanofi-Aventis, headquartered in Paris.
Scope
- The deal is valued at $613m and includes the upfront payment of $50m which Glenmark will receive. Of this payment, $25 million will be paid on the closure of the transaction, followed by a second tranche of $25m, which is contingent upon Sanofi- Aventis's positive assessment of certain data to be provided by Glenmark. When the drug is launched in the market it is estimated to have a market value of $2–3 billion
Reasons to buy
- It’s a first ever deal for Sanofi- Aventis with any Indian pharmaceutical company for Biologics in India
|
|
|
|
